RRX-001
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205870

CAS#: 925206-65-1

Description: RRX-001, also known as ABDNAZ, is a dinitroazetidine derivative with potential radiosensitizing activity. Upon administration, RRx-001 is able to dilate blood vessels, thereby increasing tumor blood flow and thus improving oxygenation to the tumor site. By increasing oxygen levels, these tumor cells may be more susceptible to radiation therapy. Tumor hypoxia is correlated with tumor aggressiveness, metastasis and resistance to radiotherapy.


Chemical Structure

img
RRX-001
CAS# 925206-65-1

Theoretical Analysis

MedKoo Cat#: 205870
Name: RRX-001
CAS#: 925206-65-1
Chemical Formula: C5H6BrN3O5
Exact Mass: 266.94908
Molecular Weight: 268.02224
Elemental Analysis: C, 22.41; H, 2.26; Br, 29.81; N, 15.68; O, 29.85

Size Price Shipping out time Quantity
10mg USD 450 2 Weeks
200mg USD 1450 2 Weeks
500mg USD 2450 2 Weeks
1g USD 3450 2 Weeks
2g USD 5950 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-26. Prices are subject to change without notice.

RRX001, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: RRX001; RRX 001; RRx-001; ABDNAZ

IUPAC/Chemical Name: 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone

InChi Key: JODKFOVZURLVTG-UHFFFAOYSA-N

InChi Code: InChI=1S/C5H6BrN3O5/c6-1-4(10)7-2-5(3-7,8(11)12)9(13)14/h1-3H2

SMILES Code: O=[N+](C1([N+]([O-])=O)CN(C(CBr)=O)C1)[O-]

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 268.02224 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

 1: Oronsky B, Scicinski J, Cabrales P, Minchinton A. RRx-001, an epigenetic-based radio- and chemosensitizer, has vascular normalizing effects on SCCVII and U87 tumors. Clin Epigenetics. 2016 May 11;8:53. doi: 10.1186/s13148-016-0220-7. PubMed PMID: 27175220; PubMed Central PMCID: PMC4864927.

2: Zhao H, Ning S, Scicinski J, Oronsky B, Knox SJ, Peehl DM. Epigenetic effects of RRx-001: a possible unifying mechanism of anticancer activity. Oncotarget. 2015 Dec 22;6(41):43172-81. doi: 10.18632/oncotarget.6526. PubMed PMID: 26657731; PubMed Central PMCID: PMC4791224.

3: Zhao H, Ning S, Nolley R, Scicinski J, Oronsky B, Knox SJ, Peehl DM. The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry. Clin Epigenetics. 2017 Jan 19;9:4. doi: 10.1186/s13148-017-0312-z. PubMed PMID: 28149332; PubMed Central PMCID: PMC5270305.

4: Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox SJ, Peehl D, Zhao H, Ning S, Cabrales P, Summers TA Jr, Reid TR, Fitch WL, Kim MM, Trepel JB, Lee MJ, Kesari S, Abrouk ND, Day RM, Oronsky A, Ray CM, Carterg CA. RRx-001: a systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in Phase II clinical trials. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi: 10.1080/13543784.2017.1268600. PubMed PMID: 27935336.

5: Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid TR, Trepel JB, Abrouk ND, Larson C, Oronsky A, Lybeck HE, Day RM, Carter CA. A Partial Response to Reintroduced Chemotherapy in a Resistant Small Cell Lung Cancer Patient After Priming with RRx-001. Clin Med Insights Oncol. 2016 Nov 6;10:105-108. PubMed PMID: 27840583; PubMed Central PMCID: PMC5098407.

6: Fens MH, Cabrales P, Scicinski J, Larkin SK, Suh JH, Kuypers FA, Oronsky N, Lybeck M, Oronsky A, Oronsky B. Targeting tumor hypoxia with the epigenetic anticancer agent, RRx-001: a superagonist of nitric oxide generation. Med Oncol. 2016 Aug;33(8):85. doi: 10.1007/s12032-016-0798-9. PubMed PMID: 27377482.

7: Cabrales P, Scicinski J, Reid T, Kuypers F, Larkin S, Fens M, Oronsky A, Oronsky B. A look inside the mechanistic black box: Are red blood cells the critical effectors of RRx-001 cytotoxicity? Med Oncol. 2016 Jul;33(7):63. doi: 10.1007/s12032-016-0775-3. PubMed PMID: 27229330.

8: Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. RRx-001, A novel dinitroazetidine radiosensitizer. Invest New Drugs. 2016 Jun;34(3):371-7. doi: 10.1007/s10637-016-0326-y. Review. PubMed PMID: 26841903; PubMed Central PMCID: PMC4859863.

9: Scicinski J, Oronsky B, Ning S, Knox S, Peehl D, Kim MM, Langecker P, Fanger G. NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001. Redox Biol. 2015 Dec;6:1-8. doi: 10.1016/j.redox.2015.07.002. Review. PubMed PMID: 26164533; PubMed Central PMCID: PMC4529402.

10: Carter CA, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid TR, Brzezniak C. Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets. Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. PubMed PMID: 27403127; PubMed Central PMCID: PMC4924447.

11: Ning S, Sekar TV, Scicinski J, Oronsky B, Peehl DM, Knox SJ, Paulmurugan R. Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001. Oncotarget. 2015 Aug 28;6(25):21547-56. PubMed PMID: 26280276; PubMed Central PMCID: PMC4673285.

12: Carter CA, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C. Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC. Respir Med Case Rep. 2016 Apr 24;18:62-5. doi: 10.1016/j.rmcr.2016.04.007. PubMed PMID: 27330954; PubMed Central PMCID: PMC4913156.

13: Reid T, Oronsky B, Scicinski J, Scribner CL, Knox SJ, Ning S, Peehl DM, Korn R, Stirn M, Carter CA, Oronsky A, Taylor MJ, Fitch WL, Cabrales P, Kim MM, Burris HA 3rd, Lao CD, Abrouk NE, Fanger GR, Infante JR. Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study. Lancet Oncol. 2015 Sep;16(9):1133-42. doi: 10.1016/S1470-2045(15)00089-3. PubMed PMID: 26296952.

14: Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol. 2016 Mar 10;9(1):164-70. doi: 10.1159/000444633. PubMed PMID: 27065848; PubMed Central PMCID: PMC4821155.

15: Brzezniak C, Schmitz BA, Peterson PG, Degesys A, Oronsky BT, Scicinski JJ, Caroen SZ, Carter CA. RRx-001-Induced Tumor Necrosis and Immune Cell Infiltration in an EGFR Mutation-Positive NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors: A Case Report. Case Rep Oncol. 2016 Jan 15;9(1):45-50. doi: 10.1159/000443605. PubMed PMID: 26933418; PubMed Central PMCID: PMC4748757.

16: Carter CA, Oronsky BT, Caroen SZ, Scicinski JJ, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C. Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. Case Rep Oncol. 2016 Jan 28;9(1):62-7. doi: 10.1159/000443725. PubMed PMID: 26933421; PubMed Central PMCID: PMC4772628.

17: Das DS, Ray A, Das A, Song Y, Tian Z, Oronsky B, Richardson P, Scicinski J, Chauhan D, Anderson KC. A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia. 2016 Nov;30(11):2187-2197. doi: 10.1038/leu.2016.96. PubMed PMID: 27118403; PubMed Central PMCID: PMC5093055.

18: Yalcin O, Oronsky B, Carvalho LJ, Kuypers FA, Scicinski J, Cabrales P. From METS to malaria: RRx-001, a multi-faceted anticancer agent with activity in cerebral malaria. Malar J. 2015 May 28;14:218. doi: 10.1186/s12936-015-0720-5. PubMed PMID: 26017006; PubMed Central PMCID: PMC4453052.

19: Kim MM, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter CA, Oronsky A, Knox SJ, Caroen S, Oronsky B, Scicinski J, Lawrence TS, Lao CD. Whole Brain Radiotherapy and RRx-001: Two Partial Responses in Radioresistant Melanoma Brain Metastases from a Phase I/II Clinical Trial: A TITE-CRM Phase I/II Clinical Trial. Transl Oncol. 2016 Apr;9(2):108-13. doi: 10.1016/j.tranon.2015.12.003. PubMed PMID: 27084426; PubMed Central PMCID: PMC4833892.

20: Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Rockets, radiosensitizers, and RRx-001: an origin story part I. Discov Med. 2016 Mar;21(115):173-80. PubMed PMID: 27115167.



Additional Information

RRx-001 , a derivative of a geminal dinitroazetidine, has demonstrated promise as a novel cancer therapeutic agent in a number of cell lines and tumor models and is proposed to enter a Phase I clinical trial in cancer patients.  RRx-001 is believed to elicit an anticancer effect through nitrogen oxides released from decomposition of conjugates formed in vivo.